Clinical and histological features of lupus nephritis induced by anti-TNF therapy
Authors:
Open Access
- 17 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 1 (4) , 221-224
Abstract
It is known that anti-TNFα therapy has opened a new era in treatment of rheumatoid arthritis, and it is emerging as a new successful treatment in the current rheumatologic practice. Besides, there is evidence that this therapy is an important cause of iatrogenic autoimmune disease. Several studies reported the possible onset of lupus syndrome that can be resolved with withdrawal of anti-TNFα drugs. Our report describes the first lupus nephritis case developing in a rapidly progressive renal failure that required haemodialysis treatment in a patient affected with rheumatoid arthritis, treated with anti-TNFα therapy. So, we confirm the importance of a careful clinic and immunologic evaluation before starting anti-TNFα therapy.Keywords
This publication has 10 references indexed in Scilit:
- Entwicklung eines systemischen Lupus erythematodes mit fokaler proliferativer Lupusnephritis unter einer Anti-TNF-α-Therapie bei PsoriasisarthritisMedizinische Klinik, 2007
- Autoimmune Diseases Induced by TNF-Targeted TherapiesMedicine, 2007
- Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritisNephrology Dialysis Transplantation, 2005
- Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.2005
- The Classification of Glomerulonephritis in Systemic Lupus Erythematosus RevisitedJournal of the American Society of Nephrology, 2004
- Drug-induced systemic lupus erythematosus associated with etanercept therapyThe Lancet, 2002
- Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodiesArthritis & Rheumatism, 2000
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 miceClinical Immunology and Immunopathology, 1989